Browsing by Subject/keywords Clinical Trial

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
PreviewIssue DateTitle / NameAuthor(s)Type
2021Improving recruitment to clinical trials for regional and rural cancer patients through a regionally based clinical trials networkMuthusamy, Arun; Long, Donna; Underhill, Craig RJournal Article 
2021MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum SensitivitySpigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et alConference Paper 
Nivolumab and Ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma.pdf.jpg30-Aug-2024Nivolumab and Ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancerKlein, O.; Carlino, M. S.; Brown, M. P.; Harris, S.; Gunjur, A., et alConference Poster 
2021P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line SettingPaz-Ares, Luis; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et alConference Paper 
2021Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based studyTung, Iris; Moldovan, Cristina; Wong, Vanessa; De Boer, Richard; Gibbs, Peter, et alConference Paper 
2020Real-world uptake of bone modifying agents in advanced breast cancer with bone metastases-Prospective data from a multi-site Australian registryWong, Vanessa; De Boer, Richard; Anton, Angelyn; Malik, Laeeq; Greenberg, Sally, et alConference Paper 
2020RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC)Ponce, Santiago; Brendel, K.; Spigel, David R.; Chen, Yuanbin; Jove Casulleras, M., et alConference Paper 
2020RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivitySpigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et alConference Paper 
2020RESILIENT part II: An open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapySpigel, David R.; Paz-Ares, Luis G.; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et alConference Paper